In a subsequent dose expansion phase of the study, the safety and preliminary antitumor activity of tovorafenib were further evaluated in cohorts of patients with BRAF-mutant, NRAS-mutant and BRAF/NRAS wild-type metastatic melanoma. This evidence concerns the gene NRAS and metastatic melanoma.